A Study of Carbon 13-based Deep Labelling of Bone Marrow Cells
For patients and families
In plain language
An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.
- What is being studied
- The protocol lists: Non-Interventional Study.
- Who it may be relevant to
- Registry conditions: Monoclonal Gammopathy of Undetermined Significance (MGUS), Non-IgM Monoclonal Gammopathy of Undetermined Significance. Basic parameters: from 18 years · All.
- What needs checking
- Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
- Where it takes place
- United States
- Next step
- Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →
Unsure about the terms? Read our patient guide →
Official title
A Pilot Study of 13Carbon-Based Deep Labeling of Bone Marrow Cells to Map Their Utilization of Extracellular Metabolites
Overview
This study evaluates a novel laboratory method to study how certain bone marrow cells in the body take up nutrients from their environment.
Detailed description
PRIMARY OBJECTIVE:
I. Evaluate differences in the amount of extracellular uptake of glucose and amino acids (AAs) between pre-malignant clonal plasma cells (cPCs) and polyclonal plasma cells (pPCs).
OUTLINE: This is an observational study. Participants are assigned to 1 of 2 groups.
GROUP I: Patients undergo blood collection and bone marrow aspiration as part of their standard care and have their medical records reviewed on study.
GROUP II: Healthy volunteers undergo blood collection and bone marrow aspiration on study.
Interventions
- Other Non-Interventional Study
Non-interventional study
Primary outcome measures
- Extracellular uptake of glucose and amino acids (AAs) between pre-malignant clonal plasma cells (cPCs) and polyclonal plasma cells (pPCs) [Time frame: Up to 30 days]
Eligibility criteria
Inclusion criteria
- All Participants:
- At least age 18 years or older
- Able to provide informed consent
- MGUS Cohort:
- International Myeloma Working Group (IMWG) criteria for the diagnosis of non-IgM MGUS
Exclusion criteria
- All Participants:
- Unable to provide consent
- Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) >1
- Prior history of adverse events with conscious sedation
- Ongoing use of immunosuppressive medications
- All known pregnant and lactating women will be excluded
Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.
Healthy volunteers: Yes
Study design
- Observational model
- Case-control
Study locations
United States · 1 center
- Mayo Clinic in Rochester — Rochester
Identifiers
NCT: NCT07057583 · 24-003478 · NCI-2025-01095 · 24-003478 · HT9425-24-1-0619